Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T‐Cell Lymphoma or Adult T‐Cell Lymphoma
Authors:
- 16 December 2019
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 60 (1) , 58-66
Abstract
Cutaneous T‐cell lymphoma (CTCL) and adult T‐cell leukemia/lymphoma (ATL) are rare non‐Hodgkin lymphomas commonly expressing C‐C chemokine receptor 4 (CCR4). Mogamulizumab is a humanized monoclonal antibody against CCR4 approved in the United States for the treatment of patients with relapsed/refractory mycosis fungoides or Sézary syndrome, the most common forms of CTCL. Pharmacokinetic (PK) and clinical study data from 444 adult patients with ATL or CTCL collected during 6 clinical trials of mogamulizumab were used to construct a population PK model, which was best described by a 2‐compartment model with linear clearance. Albumin, aspartate aminotransferase, mild‐to‐moderate hepatic impairment, and sex were statistically significant predictors of clearance; albumin was also a statistically significant predictor of peripheral volume of distribution; and body surface area was a statistically significant predictor for central volume of distribution. None of the other covariates—for example, age, body weight, body mass index, bilirubin, creatinine clearance, disease type (ATL and CTCL), ATL subtype (acute, lymphoma, and chronic), CTCL subtype (mycosis fungoides and Sézary syndrome), CCR4 expression (status or degree), race (Japanese and non‐Japanese), renal impairment (normal, mild, moderate, and severe), or performance status—had a statistically significant impact. Performance of the final population PK model was acceptable. This model will be valuable for guiding further studies of mogamulizumab.Keywords
Funding Information
- Kyowa Kirin Pharmaceutical Development, Inc., Princeton, New Jersey
This publication has 19 references indexed in Scilit:
- Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell LymphomaJournal of Clinical Oncology, 2010
- Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/LymphomaClinical Cancer Research, 2010
- Evaluation of different tests based on observations for external model evaluation of population analysesJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Extensions to the Visual Predictive Check to facilitate model performance evaluationJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, UnspecifiedClinical Cancer Research, 2004
- Increased CCR4 Expression in Cutaneous T Cell LymphomaJournal of Investigative Dermatology, 2002
- A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and childrenBritish Journal of Clinical Pharmacology, 2000
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981